Intravitreal Triamcinolone Acetonide Injection for Treatment of Refractory Diabetic Macular Edema A Systematic Review

被引:89
|
作者
Yilmaz, Taygan [1 ]
Weaver, Christopher D. [1 ]
Gallagher, Micheal J. [2 ]
Cordero-Coma, Miguel [3 ]
Cervantes-Castaneda, Rene A. [4 ]
Klisovic, Dino [5 ]
Lavaque, Alejandro J. [6 ]
Larson, Robin J. [1 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03766 USA
[2] Hermitage Med Clin, Dublin, Ireland
[3] Hosp Leon, Dept Ophthalmol, Leon, Spain
[4] CODET Vis Inst, Tijuana, Mexico
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Oftalmol Cristo Alvarez, San Miguel De Tucuman, Argentina
关键词
RANDOMIZED CLINICAL-TRIAL; RETINOPATHY; PHOTOCOAGULATION;
D O I
10.1016/j.ophtha.2009.02.002
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To compare intravitreal triamcinolone acetonide (IVTA) injection versus no treatment or sub-Tenon triamcinolone acetonide (STTA) injection in improving visual acuity (VA) of patients with refractory diabetic macular edema (DME; unresponsive to focal laser therapy). Clinical Relevance: Diabetic macular edema is the leading cause of visual loss in diabetic retinopathy. Laser therapy has been the standard of care for patients with persistent or progressive disease. More recently, it has been suggested that IVTA injection may improve VA. Methods and Literature Reviewed: The following databases were searched: Medline (1950-September Week 2 2008), The Cochrane Library (Issue 3, 2008), and the TRIP Database (up to September 1, 2008), using no language or other limits. Randomized controlled trials were included that consisted of patients with refractory DME, those comparing IVTA injection with no treatment or STTA injection, those reporting VA outcomes, and those having a minimum follow-up of 3 months. Results: In the 4 randomized clinical trials comparing IVTA injection with placebo or no treatment, IVTA injection demonstrated greater improvement in VA at 3 months, but the benefit was no longer significant at 6 months. Those who received IVTA injection had significantly higher IOP at 3 months and at 6 months. In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. Intravitreal triamcinolone acetonide injection demonstrated no difference in IOP at 3 months or at 6 months. Conclusions: Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:902-913 (C) 2009 by the American Academy of Ophthalmology.
引用
收藏
页码:902 / 911
页数:10
相关论文
共 50 条
  • [41] Effect of intravitreal triamcinolone injection on diabetic macular edema
    Wagner, J
    Sacu, S
    Krepler, K
    Richter-Müksch, S
    Wedrich, A
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U368 - U368
  • [42] Intravitreal injection of triamcinolone for diffuse diabetic macular edema
    Jonas, JB
    Kreissig, I
    Söfker, A
    Degenring, RF
    ARCHIVES OF OPHTHALMOLOGY, 2003, 121 (01) : 57 - 61
  • [43] Intravitreal Triamcinolone for the Treatment of Diabetic Macular Edema
    Gomez-Ulla, Francisco
    Marticorena, Joaquin
    Alfaro, D. Virgil, III
    Fernandez, Maribel
    Mendez, Elizabeth Rodriguez
    Rothen, Michelle
    CURRENT DIABETES REVIEWS, 2006, 2 (01) : 99 - 112
  • [44] Treatment of refractory macular edema with intraocular triamcinolone acetonide
    Kurz, PA
    Moorthy, RS
    Fountain, JA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U101 - U101
  • [45] Pars plana vitrectomy combined with intravitreal triamcinolone acetonide injection for diabetic diffuse macular edema
    Foltran, F
    Prosdocimo, G
    Lo Giudice, G
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [46] Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema
    Mauro Cellini
    Alberto Pazzaglia
    Eugenio Zamparini
    Pietro Leonetti
    Emilio C Campos
    BMC Ophthalmology, 8
  • [47] Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema
    Masakazu Morioka
    Yoshihiro Takamura
    Yutaka Yamada
    Takehiro Matsumura
    Makoto Gozawa
    Masaru Inatani
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256 : 2301 - 2307
  • [48] Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
    Marey, Hatem M.
    Ellakwa, Amin F.
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 1011 - 1016
  • [49] Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema
    Morioka, Masakazu
    Takamura, Yoshihiro
    Yamada, Yutaka
    Matsumura, Takehiro
    Gozawa, Makoto
    Inatani, Masaru
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 256 (12) : 2301 - 2307
  • [50] Intravitreal triamcinolone acetonide of triaminolone for the treatment of diabetic refractory macular edema: Early effect on central macular thickness and visual acuity
    Audren, F
    Massin, P
    Haouchine, B
    Erginay, A
    Bergmann, JF
    Gaudric, A
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U415 - U415